Skip to content

Evidence based evaluation of the intervention of Qingxin Jieyu Formula in patients with enhanced inflammatory response in non-ST-segment elevated myocardial infarction

Evidence based evaluation of the intervention of Qingxin Jieyu Formula in patients with enhanced inflammatory response in non-ST-segment elevated myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000066
Enrollment
Unknown
Registered
2024-05-19
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-ST-segment elevated myocardial infarction

Interventions

Trial Group:conventional therapy combine with Qing-Xin-Jie-Yu Granule
Placebo group:conventional therapy combine with placebo

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)35 years = age =75 years 2)The diagnostic criteria of non-ST-segment elevation myocardial infarction were met 3)The syndrome differentiation of TCM belongs to the syndrome of stasis and toxin 4)hs-CRP=2mg/L 5)Volunteer and sign the informed consent form

Exclusion criteria

Exclusion criteria: Subjects will be excluded from the study if they meet any of the following criteria: Presence of primary cardiomyopathy, infective endocarditis, or other heart diseases not caused by coronary artery lesions. Recent history (within the past month) of infection, fever, trauma, burns, or surgery. Tendency to bleed or a reduced platelet count. Current use of antibiotics or traditional Chinese medicine for clearing heat and detoxifying. Severe heart failure with a left ventricular ejection fraction of less than 50%. Individuals with severe cardiac arrhythmias (paroxysmal ventricular tachycardia) who have experienced recent recurrent episodes. Patients with malignant tumors, active rheumatic immune diseases, or tuberculosis. Pregnant women, those planning to become pregnant, or breastfeeding women. Participation in another clinical trial within the last month, anticipated poor compliance, or allergies to any components of the study medication.

Design outcomes

Primary

MeasureTime frame
hs-CRP;

Secondary

MeasureTime frame
Seattle Angina Questionnaire;Adverse cardiovascular events;brain natriuretic peptide;ultrasonic cardiogram;interleukin-6\interleukin-1ß\tumor necrosis factor alpha\matrix metallopeptidase-9;

Countries

China

Contacts

Public ContactHao Xu

Xiyuan Hospital, China Academy of Chinese Medical Sciences

xuhaotcm@hotmail.com18601081161

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026